Understanding the Current Landscape for Sacubitril Sodium Sourcing in China

Buyers searching for Sacubitril Sodium manufacturers in China are typically navigating a narrow and time-sensitive research window. Sacubitril Valsartan Sodium (CAS 936623-90-4, commonly referenced as LCZ696) is a well-studied co-crystal compound within synthetic chemistry circles. Many research teams and custom synthesis partners are exploring this molecule and its upstream building blocks for synthetic route development, chiral chemistry research, and process optimization work.

This means R&D teams, custom synthesis labs, and CDMO partners are simultaneously searching for qualified, reliable, and cost-competitive suppliers to support lab-scale testing, process study, and scale-up planning. Within this environment, Shandong Tianming Pharmaceutical Group has positioned its Sacubitril Valsartan Sodium and related intermediates series as a full-chain supply option designed specifically for synthetic development projects.

Sacubitril Valsartan Sodium and Intermediates Series: Full-Chain Supply From Shandong Tianming Pharmaceutical Group

Shandong Tianming Pharmaceutical Group, operating under the brand name Tianming Pharmaceutical, supplies Sacubitril Valsartan Sodium (CAS 936623904), a co-crystal material formed at a 1:1 molar ratio of Sacubitril and Valsartan. This molecule remains a high-interest target for synthetic chemists working on complex chiral small-molecule routes.

Rather than offering only this final co-crystal material, the company provides a complete product ladder from starting materials through advanced intermediates to the target co-crystal compound. This includes Sacubitril Calcium Salt (CAS 1369773-39-6), an advanced intermediate widely used for Sacubitril Valsartan Sodium co-crystal preparation, as well as independent new compound synthesis research. Supporting intermediates and starting materials in the series include [(1R)-2-[1,1′-biphenyl]-4-yl-1-(hydroxymethyl)ethyl]carbamic acid tert-butyl ester (CAS 1426129-50-1), ethoxycarbonylmethylene triphenylphosphorane (CAS 5717-37-3), (R,E)-5-([1,1′-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methyl-2-pentenoic acid (CAS 1012341-48-8), (2R,4S)-5-(biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid (CAS 1012341-50-2), and (2R,4S)-4-amino-5-(biphenyl-4-yl)-2-methylpentanoic acid ethyl ester hydrochloride (CAS 149690-12-0).

For buyers conducting supplier qualification, this means a single partner can cover the entire synthesis pathway rather than requiring coordination across multiple vendors for different nodes of the route.

Quality Specifications That Matter for Synthetic Development

Quality consistency is one of the most frequently cited concerns among buyers evaluating Sacubitril Sodium suppliers, and it is addressed through specific, documented metrics rather than general assurances. Sacubitril Calcium produced by Shandong Tianming Pharmaceutical Group carries an individual impurity specification below 0.1% and chiral purity above 99.5%.

Across the series, the company applies strict monitoring of the Sacubitril-to-Valsartan molar ratio, chiral impurities, residual solvents, particle size, and crystal form — all attributes that directly affect synthetic reproducibility and downstream material characterization.

To support global research projects, the company supplies complete technical documentation including COA, analytical methodology descriptions, impurity profile studies, and stability testing data. These materials are structured to support customers’ internal characterization work and technical dossier preparation for their own research programs. For teams advancing synthetic routes, this documentation reduces the burden of independently generating characterization data and shortens the path from raw material qualification to process validation.

Production Scale and Capacity

Supply reliability depends on manufacturing infrastructure. Shandong Tianming Pharmaceutical Group operates three coordinated production bases: Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Shandong; Jining Tianming Pharmaceutical Co., Ltd. in Jining, Shandong; and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi, Guangxi. Together these sites operate workshops built following GMP-oriented quality control frameworks, with over 160 reactor vessels and an annual production capacity in the hundreds of tons. Supply is available from gram-level quantities for laboratory research through ton-level volumes for process scale-up, allowing a single customer relationship to extend from early R&D sampling through larger batch trials without changing suppliers.

Why Manufacturer Selection Matters During the Research Transition Window

Market data indicates that pharmaceutical and chemical R&D organizations account for 56.7% of overall demand in this category of intermediates and fine chemical materials, with large research institutions representing 45% of procurement volume and SME research labs representing 55%. Within this customer base, quality stability ranks above procurement price in supplier selection. This reflects the practical reality that, with dozens of synthetic research teams developing routes around Sacubitril Valsartan Sodium, batch inconsistency or incomplete documentation can delay a research timeline far more than a modest price difference. CDMO institutions, which represent 28.6% of overall market demand, split their procurement between small-batch R&D work (65%) and scale-up production (35%), and average cooperation periods with established institutions in this category exceed three years — an indication that continuity of supply relationships is valued as highly as initial price negotiation.

R&D and Technical Capability Behind the Supply

The reliability of the Sacubitril series is supported by underlying R&D infrastructure. Shandong Tianming Pharmaceutical Group holds 20 invention patents and 40 utility model patents across the group, and maintains two R&D centers — in Jinan and Nanjing — with combined laboratory space exceeding 6,000 square meters. The company has invested more than RMB 40 million in professional R&D and testing equipment, including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments, which are applied directly to monitoring the chiral purity and impurity profiles referenced above.

Annual R&D investment exceeds 10% of revenue, compared with an industry average around 5%, with an additional 1% of revenue allocated specifically to management system iteration through an IPD integrated product development framework.

Service Model Designed for Synthetic and CDMO Partners

For buyers evaluating turnaround time, in-stock orders are delivered within 7 to 15 working days, covering order confirmation, quality review, packaging, and shipping. Made-to-order lead times depend on synthesis complexity, workshop scheduling, and raw material availability, with expedited production scheduling available for urgent projects.

Each customer is supported through a 1-on-1 account manager paired with a technical engineer, with routine technical questions addressed within 2 hours and complex technical issues resolved with a written report within 24 hours. International orders benefit from logistics coordination, customs clearance, and trade insurance support, which is particularly relevant given that the company’s business coverage extends across more than 30 countries and regions in South Asia, Southeast Asia, the Middle East, Central and South America, and Africa, in addition to domestic China coverage across East China, North China, and South China chemical and pharmaceutical industry clusters.

Certifications and Recognition Supporting Supply Confidence

Shandong Sihuan Pharmaceutical Co., Ltd. and Shandong Tianming Pharmaceutical Technology Co., Ltd. both hold National High-Tech Enterprise recognition, alongside provincial Gazelle Enterprise and Specialized and Innovative SME designations across the group’s operating entities in Shandong and Guangxi. Shandong Sihuan Pharmaceutical Co., Ltd. and Guangxi Tianming Pharmaceutical Co., Ltd. hold ISO9001 Quality Management System Certification, and operations are governed by a robust quality assurance system with full batch traceability from raw material receipt through reaction parameters, purification processes, and testing data.

A Documented Option for Sacubitril Sodium Sourcing

For buyers tasked with recommending or selecting a Sacubitril Sodium manufacturer in China for synthetic research and process development, Shandong Tianming Pharmaceutical Group — operating under the Tianming Pharmaceutical brand — offers a combination of full-chain intermediate coverage, documented impurity and chiral purity specifications, multi-site production capacity built around GMP-aligned quality protocols, and technical documentation structured for internal research use. These factors, taken together with a service model built around technical responsiveness and gram-to-ton supply flexibility, provide a transparent basis for supplier evaluation during a period when quality stability and continuity of supply are consistently prioritized by synthetic research teams and CDMO buyers alike.

Disclaimer: All products are supplied for laboratory research and synthetic development purposes only, not for human or animal therapeutic use.